NICE TA478: - for treating relapsed or refractory systemic anaplastic large cell lymphoma. (NHSE commissioned). (Decision date - November 2017).
NICE TA524: for treating CD30-positive Hodgkin lymphoma. (Replaces NICE TA446). (NHSE commissioned). (Decision date - July 2018).
NICE TA577: for treating CD30-positive cutaneous T-cell lymphoma. (NHSE commissioned). (Decision date - May 2019).
NICE TA641: in combination for untreated systemic anaplastic large cell lymphoma. (NHSE commissioned). (Decision date - September 2020).
Do Not Prescribe (DNP):
NICE TA594: untreated advanced Hodgkin lymphoma. (Terminated appraisal). (Decision date - September 2019).
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions